Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Absci Corporation (ABSI : NSDQ)

• Company Description    Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design. Absci Corporation is based in NEW YORK. Number of Employees: 157

• Price / Volume Information    Yesterday's Closing Price: $2.74 Daily Weekly Monthly 20 Day Moving Average: 3,868,122 shares Shares Outstanding: 149.52 (millions) Market Capitalization: $409.69 (millions) Beta: 2.01 52 Week High: $6.33 52 Week Low: $2.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.67% -10.32% 12 Week -0.36% -9.54% Year To Date 4.58% -6.63%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 18105 SE MILL PLAIN BLVD - VANCOUVER,WA 98683 USA ph: 360-949-1041 fax: - investors@absci.com http://www.absci.com

• General Corporate Information    Officers Sean McClain - Chief Executive Officer and Director Zachariah Jonasson - Chief Financial Officer Todd Bedrick - Chief Accounting Officer Frans van Houten - Director Karen McGinnis - Director Peer Information Absci Corporation (CORR.) Absci Corporation (RSPI) Absci Corporation (CGXP) Absci Corporation (BGEN) Absci Corporation (GTBP) Absci Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00091E109 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 149.52 Most Recent Split Date: (:1) Beta: 2.01 Market Capitalization: $409.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.78 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.02 Price/Cash Flow: - Price / Sales: 99.01 EPS Growth vs. Year Ago Period: -9.09% vs. Previous Quarter: -14.29% Sales Growth vs. Year Ago Period: -53.31% vs. Previous Quarter: -49.70% ROE 06/30/25 - -60.21 03/31/25 - -53.69 12/31/24 - -48.98 ROA 06/30/25 - -50.85 03/31/25 - -45.89 12/31/24 - -42.12 Current Ratio 06/30/25 - 4.39 03/31/25 - 5.72 12/31/24 - 4.67 Quick Ratio 06/30/25 - 4.39 03/31/25 - 5.72 12/31/24 - 4.67 Operating Margin 06/30/25 - -2,737.94 03/31/25 - -2,232.13 12/31/24 - -2,274.06 Net Margin 06/30/25 - -2,737.94 03/31/25 - -2,232.13 12/31/24 - -2,274.06 Pre-Tax Margin 06/30/25 - -2,733.47 03/31/25 - -2,231.01 12/31/24 - -2,272.52 Book Value 06/30/25 - 1.36 03/31/25 - 1.56 12/31/24 - 1.56 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.01 Debt-to-Capital 06/30/25 - 0.09 03/31/25 - 0.34 12/31/24 - 0.70

Powered by Zacks Investment Research ©